United States Health

MINISO Group (NYSE:MNSO) reported preliminary mainland China gross merchandise value growth of 25%–30% year over year for the third quarter of 2026.

Johnson & Johnson (NYSE:JNJ) reported two-year Phase 3 ICONIC-LEAD results showing at least 72% of ICOTYDE-treated patients achieved PASI 90 at Week 112.

Eli Lilly and Company (NYSE:LLY) reported exploratory Phase 3b results from the TOGETHER-PsO study comparing Taltz plus Zepbound with Taltz alone in adults with moderate-to-severe plaque psoriasis and excess weight.

High Tide (NASDAQ:HITI) completed the acquisition of an established cannabis retail store in Chestermere, Alberta, for $670,000 in cash on October 8, 2026.

Humana (NYSE:HUM) shares jumped 14.4% to $443 in premarket trading after U.S. government data showed 95% of its members were in Medicare Advantage plans rated four stars or higher for 2027.

Alumis (NASDAQ:ALMS) reported new Phase 3 ONWARD results for envudeucitinib showing 54% of patients achieved complete skin clearance at Week 48.

Pacira BioSciences (NASDAQ:PCRX) agreed to be acquired by Viatris (NASDAQ:VTRS) for $36.50 per share in cash through a tender offer, valuing Pacira’s equity at approximately $1.65 billion.

Glaukos (NYSE:GKOS) entered an exclusive license agreement with RevOpsis Therapeutics to develop and commercialize RO-104 for neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion.

Bristol Myers Squibb (NYSE:BMY) reported positive Phase 3 EXCALIBER-RRMM results showing median progression-free survival of 42 months with ZENBEXUS-based treatment versus 20 months with the comparator regimen.

AngioDynamics (NASDAQ:ANGO) reported fiscal first-quarter 2027 net sales of $80.9 million, up 6.9% from the prior-year period.

Taiwan Semiconductor Manufacturing (NYSE:TSM) reported third-quarter 2026 revenue of NT$1.49 trillion, or about $46.7 billion, representing roughly 51% year-over-year growth and exceeding analyst expectations of NT$1.46 trillion.

Biohaven (NYSE:BHVN) entered an exclusive regional licensing agreement with Ono Pharmaceutical covering its IgG degrader portfolio, with near-term payments of up to $100 million.